Merck & Co./$MRK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Merck & Co.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Ticker
$MRK
Sector
Primary listing
NYSE
Employees
74,000
Headquarters
Website
Merck & Co. Metrics
BasicAdvanced
$217B
13.42
$6.49
0.37
$3.24
3.72%
Price and volume
Market cap
$217B
Beta
0.37
52-week high
$103.70
52-week low
$73.31
Average daily volume
12M
Dividend rate
$3.24
Financial strength
Current ratio
1.424
Quick ratio
0.82
Long term debt to equity
69.238
Total debt to equity
71.992
Dividend payout ratio (TTM)
48.95%
Interest coverage (TTM)
18.77%
Profitability
EBITDA (TTM)
28,330
Gross margin (TTM)
77.70%
Net profit margin (TTM)
25.79%
Operating margin (TTM)
37.64%
Effective tax rate (TTM)
14.32%
Revenue per employee (TTM)
$860,000
Management effectiveness
Return on assets (TTM)
13.01%
Return on equity (TTM)
35.42%
Valuation
Price to earnings (TTM)
13.42
Price to revenue (TTM)
3.449
Price to book
4.45
Price to tangible book (TTM)
17.84
Price to free cash flow (TTM)
14.915
Free cash flow yield (TTM)
6.70%
Free cash flow per share (TTM)
5.835
Dividend yield (TTM)
3.72%
Forward dividend yield
3.72%
Growth
Revenue change (TTM)
1.82%
Earnings per share change (TTM)
20.41%
3-year revenue growth (CAGR)
3.63%
10-year revenue growth (CAGR)
4.68%
3-year earnings per share growth (CAGR)
-0.21%
10-year earnings per share growth (CAGR)
6.60%
3-year dividend per share growth (CAGR)
5.65%
10-year dividend per share growth (CAGR)
5.91%
What the Analysts think about Merck & Co.
Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.
Bulls say / Bears say
The U.S. FDA approved a new subcutaneous formulation of Keytruda, called Keytruda Qlex, which provides one-to-two minute injections, improving patient convenience and clinic efficiency while extending market exclusivity for Merck's top-selling immunotherapy ahead of its 2028 patent expiration (Reuters).
Merck is in advanced talks to acquire London-based Verona Pharma for about $10 billion, gaining Ohtuvayre—a recently approved inhaled COPD treatment that made up 96% of Verona’s Q1 revenue—further diversifying Merck’s portfolio beyond oncology (Reuters).
Merck’s Q1 adjusted profit increased 7% to $5.61 billion, or $2.22 per share, surpassing analyst expectations despite a 2% revenue drop. The quarter included 5% growth in animal health and $280 million from the launch of its new lung disease drug Winrevair (Reuters).
Merck announced job cuts and cost-saving measures targeting $3 billion in annual savings by 2027, citing ongoing weakness in Gardasil vaccine demand in China. Q2 earnings fell 7% and Gardasil sales dropped 55% year-over-year (Reuters).
Merck slightly narrowed its full-year revenue guidance to $64.3 billion–$65.3 billion in its Q2 results, signaling reduced top-line visibility due to pressures from vaccines and tariffs (Reuters).
Merck lowered its adjusted EPS forecast for 2025 to $8.82–$8.97, down from previous guidance, after including $200 million in U.S. tariff costs and a licensing charge, reflecting margin pressure from geopolitical and partnership-related expenses (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Merck & Co. Financial Performance
Revenues and expenses
Merck & Co. Earnings Performance
Company profitability
Merck & Co. News
AllArticlesVideos
European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)
Business Wire5 hours ago
Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy
Business Wire1 day ago
Merck-Eisai's cancer drug combo meets one main goal in late-stage study
Reuters1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Merck & Co. stock?
Merck & Co. (MRK) has a market cap of $217B as of October 29, 2025.
What is the P/E ratio for Merck & Co. stock?
The price to earnings (P/E) ratio for Merck & Co. (MRK) stock is 13.42 as of October 29, 2025.
Does Merck & Co. stock pay dividends?
Yes, the Merck & Co. (MRK) stock pays dividends to shareholders. As of October 29, 2025, the dividend rate is $3.24 and the yield is 3.72%. Merck & Co. has a payout ratio of 48.95% on a trailing twelve-month basis.
When is the next Merck & Co. dividend payment date?
The next Merck & Co. (MRK) dividend payment date is unconfirmed.
What is the beta indicator for Merck & Co.?
Merck & Co. (MRK) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.